IOVS Annual Reviews: Physical Science Suite
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Erickson, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Erickson, K. A.
(Investigative Ophthalmology and Visual Science. 2000;41:998-1005.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Expression of Adenylate Cyclase Subtypes II and IV in the Human Outflow Pathway

Xun Zhang1, Nan Wang2, Alison Schroeder1 and Kristine A. Erickson1,3

1 From the Boston University School of Medicine, Department of Ophthalmology; the 2 New England Eye Center, Tufts University School of Medicine, Boston; and the 3 New England College of Optometry, Boston, Massachusetts.

PURPOSE. It has been demonstrated that low doses of pilocarpine and other muscarinics substantially increase outflow facility in the isolated human outflow system devoid of ciliary muscle. These cholinergic-induced facility responses were thought possibly to be due to elevation of cAMP as a result of the presence of adenylate cyclases II (AC-II) and IV (AC-IV). Therefore, whether these isoforms are present in outflow tissues was examined.

METHODS. Human anterior segments were perfused with carbachol (10-9–10-5 M), and outflow facility and cAMP levels in the perfusate were measured simultaneously. Isolated trabecular meshwork (TM) were incubated with carbachol (10-7 M), and the subsequent changes in cAMP were measured by radioimmunoassay. AC-II and AC-IV were characterized in ocular tissue with reverse transcription–polymerase chain reaction and in situ hybridization.

RESULTS. Outflow facility increased, in a dose–dependent manner, by 10%, 16%, and 27% in response to 10-9, 10-7, and 10-5 M carbachol, respectively. Similarly, cAMP increased by 9%, 70%, and 210% in response to 10-9, 10-7, and 10-5 M carbachol, respectively. In addition, cAMP levels significantly increased by 39% in isolated TM strips incubated with 10-7 M carbachol. AC-II was detected in most normal tissue examined, but not in any cultured cell lines or any glaucomatous tissue. AC-IV was also widely expressed in most normal tissues, faintly detected in some glaucoma tissue, but not detected in most cultured cells.

CONCLUSIONS. The presence of AC-II and AC-IV in outflow tissues supports the hypothesis that cholinergics may indeed exert an effect on outflow facility, mediated by cAMP, which is independent of muscle contraction.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Association for Research in Vision and Ophthalmology